Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CVR Medical Corp V.CVM.H

Alternate Symbol(s):  CRRVF

CVR Medical Corp. is a medical technology organization. The Company is focused on the development and advancement of technology at work within the healthcare sector. The Company’s Carotid Stenotic Scan (CSS) is a diagnostic tool designed to detect and determine a level of carotid narrowing for the purpose of identifying patients at risk for Ischemic Stroke. The CSS provides a synergistic tool, which complements other stroke screening technology such as Duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA) and computed tomography angiography (CTA). The CSS is non-invasive and does not require the use of harmful dyes. It offers its product to patients, payers, and healthcare providers.


TSXV:CVM.H - Post by User

Bullboard Posts
Comment by Aquaman11on Dec 29, 2018 1:24pm
46 Views
Post# 29168037

RE:RE:RE:RE:Just for Fun

RE:RE:RE:RE:Just for Fun
Forgot, this sales' projection table is for US sales only... 

You can throw in the discussions with China and Korea ...and others according to page 21 of this updated version:  https://cvrmed.com/wp-content/uploads/2018/11/CVR-Medical-Investor-Overview-November-2018.pdf

Even with the 7% royalty fee to CVR Global, add further dilution (the way things are with them and those sort of startups), you do the math...

I also like the trial program they seem to be aiming at (p.21).

There is a big profit to be made by the clinics and hospitals that would be acquiring this device (if it delivers the way they say it does) ...and we know those people are in it for profit.

The 3-5 year horizon seems to be the interesting one; patience is a virtue.
Bullboard Posts